Discover investment opportunities in Big Pharma Stocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Big Pharma Stocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Big Pharma Stocks using our Smart AI Filter.
10 stocks found for "Big Pharma Stocks"
Security name | Expected returns | Sharpe Ratio | Beta | Volatility | P/E Ratio | Dividend Yield |
|---|---|---|---|---|---|---|
0.67 | ±23.5% | 9.8 | 18.34% | |||
0.45 | ±20.5% | 12.7 | 3.02% | |||
0.33 | ±27.9% | 8.6 | 4.00% | |||
0.49 | ±18.7% | 14.5 | 12.70% | |||
0.60 | ±27.2% | 15.6 | 3.47% | |||
0.22 | ±27.3% | 15.0 | 2.83% | |||
0.32 | ±24.8% | 8.7 | 6.75% | |||
0.37 | ±19.7% | 14.7 | 3.18% | |||
0.59 | ±31.6% | 34.5 | 0.77% | |||
0.35 | ±28.9% | 6.7 | 5.29% |
This search uses our Smart AI Filter to identify stocks matching your criteria. Results are ranked by relevance and include key financial metrics to help you make informed investment decisions.
Get personalized stock recommendations, save custom screens, and access premium filters. All our screening tools are free—signing up gives you more personalized results and the ability to save your research.
Compliance disclosure:
The securities listed on this website have not paid to be included in the results. The inclusion of any securities in the results shown does not imply any relationship with PortfolioPilot. The order of the results is ranked based on the Sharpe Ratio, which is a measure of risk-adjusted return. Please note that these listings are not recommendations or financial advice. Past performance is not indicative of future results.
Q: How do Pfizer's (PFE) historical dividends compare to those of Johnson & Johnson (JNJ)?
A: Pfizer has consistently paid dividends, historically offering a yield around 3-4%. Johnson & Johnson is known for its Dividend Aristocrat status, with a history of increasing dividends for over 50 years, providing a lower yield but potentially more stability. Investors should evaluate each company's financial health and payout ratio when considering dividend income.
Q: What impact does the patent cliff have on Merck (MRK) and Bristol-Myers Squibb (BMY)?
A: The patent cliff poses risks for Merck and Bristol-Myers Squibb as key drugs lose exclusivity, potentially affecting revenue. Both companies have robust R&D pipelines to counteract this, focusing on new drug approvals to mitigate patent losses. Investors may consider scrutinizing new product launches and patent expirations.
Q: In what ways does AbbVie (ABBV) benefit from its Humira drug despite biosimilar competition?
A: AbbVie benefits from Humira's historical market dominance and strong brand recognition. Despite biosimilar competition, AbbVie has diversified its portfolio and implemented strategic pricing and market strategies to retain its customer base. Investors might consider the company's diverse immunology and oncology portfolio as a buffer against biosimilar impact.
Q: What sector-specific risks do Eli Lilly (LLY) and Amgen (AMGN) face in the biotech industry?
A: Sector-specific risks for Eli Lilly and Amgen include regulatory hurdles, high R&D costs, and competitive pressures from emerging biotech firms. Both companies focus on innovation and market expansion to mitigate these risks, but careful analysis of their drug pipelines and regulatory developments is advisable for investors.
Q: How do AstraZeneca's (AZN) operations in emerging markets affect its growth prospects?
A: AstraZeneca's strong presence in emerging markets like China contributes significantly to its growth by capturing market share in fast-growing pharmaceutical sectors. This exposure offers potential upside but also carries currency and geopolitical risks that investors should consider when assessing growth potential.
Q: What are the potential economic cycle impacts on Gilead Sciences (GILD) and their revenue streams?
A: Gilead Sciences, with its focus on antivirals and therapies for chronic conditions, often experiences less cyclical revenue fluctuation due to ongoing demand for its products. However, healthcare spending can be affected by broader economic conditions, influencing long-term revenue prospects.
President Donald Trump demanded several pharmaceutical companies cut down their drug prices for American consumers Thursday, issuing a Sept. 29 deadline for the businesses to 'end the free ride of American innovation by European and other developed nations."
Read morePresident Donald Trump said he asked major pharmaceutical companies to take steps to cut U.S. drug prices within the next 60 days. It comes after Trump in May signed an executive order reviving a controversial policy that aims to slash drug costs by tying the prices of some medicine in the U.S. to the significantly lower ones abroad.
Read more